Dacemazine
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number |
|
PubChem CID | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H16N2OS |
Molar mass | 284.38 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
NY (what is this?) (verify) |
Dacemazine (INN, also known as Ahistan and Histantine)[1] is a phenothiazine derivative which acts as a histamine antagonist at the H1 subtype. First described in 1951, it was never marketed as a drug on its own, although a combination of dacemazine and di-tert-butylnaphthalenesulfonate was sold as an antispasmodic and antitussive under the trade name Codopectyl.[1] It was also assessed as a possible anticancer drug.[2]
References
- 1 2 Triggle DJ, Ganellin CR, MacDonald F (1996). Dictionary of Pharmacological Agents. Vol. 1. Boca Raton: Chapman & Hall/CRC. p. 711. ISBN 0-412-46630-9. Retrieved on August 2, 2008 through Google Book Search.
- ↑ Karolyhazy G, Havas I, Jansco G, Kapas L, Sellei C (August 1952). "[The anticarcinogenic effect of dimethylaminoacetyl-phentiazide (ahistan)]". Kiserletes Orvostudomany (in Romanian). 4 (4): 260–2. PMID 13023855.
Histamine receptor modulators | |||||
---|---|---|---|---|---|
H1 |
| ||||
H2 |
| ||||
H3 |
| ||||
H4 |
| ||||
See also: Receptor/signaling modulators • Monoamine metabolism modulators • Monoamine reuptake inhibitors |
Classes |
|
---|---|
Antidepressants (TCAs and TeCAs) |
|
Antihistamines |
|
Antipsychotics |
|
Anticonvulsants | |
Others |
|
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.